Dice Thinks It Holds An Ace With Oral IL-17 Inhibitor In Psoriasis
The company believes it has a potential best-in-class oral drug for psoriasis in development following positive first-in-human clinical trial data. A larger Phase II study is needed.
You may also be interested in...
Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.
The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.